Modulation of GH/IGF-1 axis: Potential strategies to counteract sarcopenia in older adults
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Aging is associated with progressive decline of skeletal muscle mass and function. This condition, termed sarcopenia, is associated with several adverse outcomes, including loss of autonomy and mortality. Due to the high prevalence of sarcopenia, a deeper understanding of its pathophysiology and possible remedies represents a high public health priority. Evidence suggests the existence of a relationship between declining growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels and age-related changes in body composition and physical function. Therefore, the age-dependent decline of GH and IGF-1 serum levels may promote frailty by contributing to the loss of muscle mass and strength. Preclinical studies showed that infusion of angiotensin II produced a marked reduction in body weight, accompanied by decreased serum and muscle levels of IGF-1. Conversely, overexpression of muscle-specific isoform of IGF-1 mitigates angiotensin II-induced muscle loss. Moreover, IGF-1 serum levels have been shown to increase following angiotensin converting enzyme inhibitors (ACEIs) treatment. Here we will review the most recent evidence regarding age-related changes of the GH/IGF-1 axis and its modulation by several interventions, including ACEIs which might represent a potential novel strategy to delay the onset and impede the progression of sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488 · cited 1×
“IL-6 is a pro-inflammatory cytokine upregulated with age (Ershler and Keller, 2000), that has been associated with increased mortality (Harris et al., 1999) and disability (Ferrucci et al., 1999) in the elderly.”
BackgroundVisser, M., Pahor, M., Taaffe, D. R., Goodpaster, B. H., Simonsick, E. M., Newman, A. B., Nevitt, M., & Harris, T. B. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m326 · Cited by 1,294
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282
Musarò, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E. R., L Sweeney, H., & Rosenthal, N. (2001) · Nature Genetics · doi:10.1038/84839 · Cited by 1,137 · cited 2×
“…systemic administration of IGF-1 results in controversial findings on muscle strength and function, transgenic overexpression of IGF-1 has been shown to exert beneficial effects on skeletal muscle (Musaro et al., 2001; Barton et al., 2002; Gregorevic et al., 2002, 2004; Schertzer et al., 2006).”
BackgroundTestosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 2×
“, 2001), testosterone (Bhasin et al., 2001), and muscle overload and stretch (Goldspink et al.”
BackgroundGrowth Hormone Replacement in Healthy Older Men Improves Body Composition but Not Functional Ability
Papadakis, M. A., Grady, D., Black, D., Tierney, M. J., Gooding, G. A. W., Schambelan, M., & Grunfeld, C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-8-199604150-00002 · Cited by 474
Blackman, M. R. (2002) · JAMA · doi:10.1001/jama.288.18.2282 · Cited by 455
Onder, G., Penninx, B. W., Balkrishnan, R., Fried, L. P., Chaves, P. H., Williamson, J., Carter, C., Bari, M. D., Guralnik, J. M., & Pahor, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08024-8 · Cited by 339 · cited 3×
“Recent evidence suggests that ACEIs may induce positive changes in body composition and physical function (Onder et al., 2002; Strazzullo et al., 2003; Di Bari et al., 2004).”
BackgroundEffect of growth hormone and resistance exercise on muscle growth and strength in older men
Yarasheski, K. E., Zachwieja, J. J., Campbell, J. A., & Bier, D. M. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.268.2.e268 · Cited by 234 · cited 1×
“…persons GH administration did not affect strength, endurance or physical ability, either alone or in combination with resistance exercise training (Yarasheski et al., 1993, 1995; Deyssig et al., 1993; Taaffe et al., 1994; Papadakis et al., 1996; Thompson et al., 1998; Hennessey et al., 2001;…”
BackgroundInsulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1
Powell, D. R., Suwanichkul, A., Cubbage, M. L., DePaolis, L. A., Snuggs, M. B., & Lee, P. D. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55144-9 · Cited by 217
Association of IGF-I levels with muscle strength and mobility in older women
Cappola, A. R., Bandeen-Roche, K., Wand, G. S., Volpato, S., & Fried, L. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7868 · Cited by 205
Giannoulis, M. G., Sonksen, P. H., Umpleby, M., Breen, L., Pentecost, C., Whyte, M., McMillan, C. V., Bradley, C., & Martin, F. C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0957 · Cited by 164 · cited 1×
“Similar findings have emerged from a study by Giannoulis et al. (2006).”
ResultGene Expression in Response to Muscle Stretch
Goldspink, G., Williams, P., & Simpson, H. (2002) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200210001-00017 · Cited by 86 · cited 2×
“Goldspink et al. (2002) have shown that IGF-1 exists in at least two isoforms as a result of alternative splicing of the IGF-1 gene.”
Background
Cited by
Sarcopenia: etiology, clinical consequences, intervention, and assessment
Lang, T., Streeper, T., Cawthon, P., Baldwin, K., Taaffe, D. R., & Harris, T. B. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1059-y · Cited by 777
Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials
Marzetti, E., Calvani, R., Cesari, M., Buford, T. W., Lorenzi, M., Behnke, B. J., & Leeuwenburgh, C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.024 · Cited by 627
Self-citationSarcopenia, frailty and their prevention by exercise
Nascimento, C. M., Ingles, M., Salvador-Pascual, A., Cominetti, M. R., Gomez-Cabrera, M. C., & Viña, J. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.08.035 · Cited by 396
Yoshimura, Y., Wakabayashi, H., Yamada, M., Kim, H., Harada, A., & Arai, H. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.03.019 · Cited by 365
Sinclair, M., Gow, P. J., Grossmann, M., & Angus, P. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13549 · Cited by 316
Metadata
- Authors
- Giovannini, S., Marzetti, E., Borst, S. E., & Leeuwenburgh, C.
- Venue
- Mechanisms of Ageing and Development
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 129
- Issue
- 10
- Pages
- 593-601
- ISSN
- 0047-6374 (ISSN-L)
- OpenAlex
- W1977037979
- Cited by
- 136
- References
- 15
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.